1. Understand how DNA repair defects lead to genetic instability and cancer

2. Explain how DNA repair defects are relevant to prostate cancer prognosis and management

3. Discuss treatment of patients with metastatic castrate resistant prostate cancer with PARP inhibitors


1. Use of novel predictive biomarkers for aGVHD

2. Initial management of aGVHD

3. Utility of Ruxolitinib and Extracorporeal Photopheresis in the management of steroid-refractory aGVHD


Session date: 
08/21/2017 - 12:00pm to 1:00pm CDT
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Marquita Nelson, MD and Benjamin Derman, MD